Search by Drug Name or NDC
NDC 61755-0051-51 EYLEA HD 8 mg/.07mL Details
EYLEA HD 8 mg/.07mL
EYLEA HD is a INTRAVITREAL INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Regeneron Pharmaceuticals, Inc. The primary component is AFLIBERCEPT.
MedlinePlus Drug Summary
Aflibercept injection (Eylea, Eylea HD) is used to treat wet age-related macular degeneration (AMD; an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities), diabetic macular edema (an eye disease caused by diabetes that can lead to vision loss), and diabetic retinopathy (damage to the eyes caused by diabetes). Aflibercept injection (Eylea) is also used to treat macular edema after retinal vein occlusion (an eye disease caused by blockage of blood flow from the eye that leads to blurry vision and vision loss) and retinopathy of prematurity (ROP; an eye disease that occurs in premature infants that can lead to vision loss and blindness). Aflibercept injection is in a class of medications called vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonists. It works by stopping abnormal blood vessel growth and leakage in the eye(s) that may cause vision loss in people with certain eye conditions.
Related Packages: 61755-0051-51Last Updated: 04/28/2024
MedLinePlus Full Drug Details: Aflibercept Injection
Ziv-aflibercept injection is used in combination with other chemotherapy medications to treat cancer of the colon (large intestine) or rectum that has spread to other parts of the body. Ziv-aflibercept is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors.
Related Packages: 61755-0051-51Last Updated: 04/28/2024
MedLinePlus Full Drug Details: Ziv-aflibercept Injection
Product Information
| NDC | 61755-0051 |
|---|---|
| Product ID | 61755-051_0750f1a4-c2f7-42d1-a4f9-4e3a71ced886 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | EYLEA HD |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | aflibercept |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVITREAL |
| Active Ingredient Strength | 8 |
| Active Ingredient Units | mg/.07mL |
| Substance Name | AFLIBERCEPT |
| Labeler Name | Regeneron Pharmaceuticals, Inc |
| Pharmaceutical Class | Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761355 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 61755-0051-51 (61755005151)
| NDC Package Code | 61755-051-51 |
|---|---|
| Billing NDC | 61755005151 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (61755-051-51) / .07 mL in 1 VIAL, SINGLE-DOSE (61755-051-50) |
| Marketing Start Date | 2023-08-18 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |